| dc.description.abstract | Despite the high number of antibiotics used for the treatment of infectious disease in
animals, the development of slow release formulations presents a significant challenge, particu larly in using novel biomaterials with low cost. In this report, we studied the pharmacokinetics,
toxicity, and therapeutic activity of ceftiofur–PHBV (ceftiofur–poly(3-hydroxybutyrate-co 3-hydroxyvalerate)) in rats. The pharmacokinetic study demonstrated a sustained release of
ceftiofur into the bloodstream, with detectable levels over the minimum inhibitory concentration
for at least 17 days after a single intramuscular injection of ceftiofur–PHBV (10 mg/kg weight).
In addition, the toxicological evaluation of biochemical, hematological, and coagulation blood
parameters at the therapeutic dose demonstrated the safety of ceftiofur–PHBV, with no adverse
effects. In addition, ceftiofur–PHBV exhibited a therapeutic effect for a longer time period than
the nonencapsulated ceftiofur in rats challenged with Salmonella Typhimurium. The slow release
of ceftiofur from the ceftiofur–PHBV, its low toxicity in the blood parameters evaluated, and
the efficacy in the rats infected with Salmonella Typhimurium make ceftiofur–PHBV a strong
candidate for biotechnological applications in the veterinary industry. | |
